Key Drivers
- Strong liquidity
- Ongoing cash burn
- No revenue
AIAI Summary
ANNX has evolved from a cash-burn story into a funded, catalyst-driven biotech with runway into 2027, but the stock remains dependent on unproven late-stage data and binary clinical/regulatory outcomes, so the key takeaway is that upside hinges on clean 2026 execution rather than current fundamentals.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Ongoing cash burn
- •No revenue
ANNX has strong liquidity and modest leverage, but persistent no revenue, heavy losses, negative free cash flow, and a rich price-to-book make the stock highly speculative.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Failed rallies
- •Oversold bounce
ANNX remains in a last month downtrend with lower highs/lows, capped by $5.68-$5.75 resistance and near-term support at $5.21-$5.37, so a reclaim of $5.44-$5.52 is needed to improve the setup.
Sharp drop to a new low on 2026-05-15 after repeated failed rallies
Sentiment & News
Key News Insights:
- •GA Phase 3
- •GBS filings
- •Conference cadence
Annexon is poised for near-term catalysts, with Q4 2026 Phase 3 geographic atrophy data and planned Guillain-Barré syndrome regulatory filings driving investor focus.
This steady stream of late-stage updates should support attention on Annexon's pipeline progress and keep the stock centered on upcoming clinical readouts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings